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BACKGROUND 
Malignant cancers require the cooperation of otherwise normal cells that surround and invade 
tumors in order to grow and spread.  Tumors must not only evade the host defense, but also 
maintain a sufficient blood supply to support rapid growth and navigate a complex series of cell-
cell interactions required to undergo successful metastasis (Hanahan, D. and Weinberg, R. A., 
2000).  This requires that tumors find ways to exploit normal host cells, causing them to adopt 
behaviors which permit and even promote malignant transformation. 
Different tumor types face different obstacles they must overcome to become malignant.  These 
challenges arise from the nature of the cells themselves and the tissues in which they reside.  
Diversity exists both in the native characteristics of the tumor cells themselves and in the 
mechanisms they employ to overcome these barriers to malignancy.  Some tumors routinely 
downregulate immune surveillance molecules so that they may avoid attacks by cytotoxic T cells 
and natural killer (NK) cells (Watson, N. F. et al., 2006; Tsuruma, T. et al., 1999).  Others 
secrete high levels of factors which stimulate blood vessel growth (Demirkesen, C. et al., 2006).  
Others downregulate molecules which maintain interactions with other cells (Oka, H. et al., 
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1993).  Many of these behaviors evoked by “tumor education” represent an inappropriate 
triggering of native developmental programs within the otherwise normal cells (Lotem, J. and 
Sachs, L., 2002).   
One type of immune cell, the macrophage, plays an important role both in the development of 
normal breast tissue and in the development and spread of breast tumors.  Macrophage activity, 
stimulated by the aptly named macrophage colony stimulating factor (M-CSF), is essential for 
normal breast development, especially during pregnancy and lactation (Pollard, J. W., 1997).   
Macrophages are the most abundant immune cell in breast tumors, constituting up to 35% of 
tumor-infiltrating inflammatory cells (Tang, R. et al., 1992). These tumor associated 
macrophages (TAMs) produce factors that facilitate tumor invasion and angiogenesis, including 
matrix metalloproteinases (MMPs, (Hagemann, T. et al., 2004)) and VEGF (Eubank, T. D. et al., 
2003).  
The millieu of cytokines secreted by tumor cells, stromal cells, and infiltrating immune cells 
dictates the behavior of macrophages within the tumor and determines the factors they will 
produce.  Many tumors secrete M-CSF (Sapi, E., 2004), and this appears to be the predominant 
macrophage-trophic factor within most breast tumors.  Landmark studies showed that mice 
deficient in M-CSF were protected against breast tumor metastasis, and that metastatic activity 
could be restored by expressing M-CSF solely in the breast tissue (Lin, E. Y. et al., 2001).  We 
showed that M-CSF stimulates monocyte/macrophages to produce VEGF, which is biologically 
active and stimulates angiogenesis (Eubank, T. D. et al., 2003).   VEGF (vascular endothelial 
growth factor) is a very important factor for tumor growth—it is one of the principal factors 
responsible for stimulating blood vessel growth (angiogenesis).  Tumors which cannot generate 
VEGF or another stimulus for angiogenesis cannot grow beyond 2mm3 (Folkman, J., 1990).  
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This process by which tumor cells commandeer “normal” macrophages to perform activities that 
promote tumor malignancy have been termed “tumor education” (Pollard, J. W., 2004).   
In sharp contrast to M-CSF, GM-CSF-stimulated monocytes exhibit several anti-tumor 
behaviors.  GM-CSF enhances the ability of macrophages to present antigen and initiate an 
immune response (Armstrong, C. A. et al., 1996).  It also stimulates monocytes to secrete large 
amounts of a soluble VEGF receptor, which binds to and inactivates VEGF present in the millieu 
(Eubank, T. D. et al., 2004).  These observations have led us to speculate that we might 
manipulate macrophage behavior in vivo by altering the milieu of factors that surround them.  
We propose that the effects of locally-administered GM-CSF may alter the behavior of TAMs, 
reversing the effects of tumor education and inducing an anti-tumor phenotype (Figure 1).  
Successful application of this approach would prove the biologic plausibility of 
microenvironmental manipulation as a therapeutic modality for solid tumors. 
METHODS 
Mice.  All procedures involving mice were conducted in accordance with OSU ILACUC 
protocol regarding the use and care of experimental animals. The PyMT transgenic mice were 
purchased from Jackson Laboratories (Bar Harbor, ME). Mammary tumors from the PyMT 
transgenics were removed and orthotopically injected into normal FVB/N female mice for these 
studies. 
Tumor injections.  Primary mammary tumors from female PyMT mice were removed, 
homogenized using trypsin, filtered and cultured in DMEM containing 10% FBS, 10 μg/ml 
insulin, and 5 ng/ml rhEGF in flasks until 80% confluent. The cells were trypsinized, washed, 
and resuspended in DMEM media at 500,000 cells per 100 μl. The cell suspension was drawn 
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into insulin syringes and orthotopically injected into the number four mammary fat pads of 
normal female FVB/N mice. 
Treatment study.  After the tumors became palpable (about 4 weeks), either PBS or 1, 10 100, or 
1000 ng rmGM-CSF in 50 μls was administered using an insulin syringe directly into the tumor. 
A total of seven treatments were administered (three times per week). The largest tumor 
dimension and mouse weight was measured weekly. For studies analyzing the effect of 
neutralizing sVEGFR-1 in combination with GM-CSF treatment, tumors were orthotopically 
injected in the same manner. After they became palpable, either PBS, 100 ng rmGM-CSF, 100 
ng rmGM-CSF + 4 μg anti-VEGF receptor-1 neutralizing antibody, 100 ng rmGM-CSF + 4 μg 
isotype IgG control (goat), or 4 μg anti-VEGF receptor-1 neutralizing antibody in 50 μl was 
injected directly into the tumors using insulin syringes. 
EPR oximetry.  Lithium octa-n-butoxy 2,3-naphthalocyanine (LiNc-BuO) microcrystals were a 
gift from Dr. Periannan Kuppusamy, The Ohio State University. The PyMT tumor cells were 
prepared as the previous treatment study. 10 mg microcrystals were resuspended in 500 μl 
DMEM and vortexed copiously. 25 μl of this suspension was added to 5x105 PyMT cells for 
each 100 μl injection. Oxygen measurements were performed immediately, and then weekly 
following treatment with rmGM-CSF using in vivo EPR oximetry. Measurements of tumor 
oxygenation was performed non-invasively using an L-band in vivo EPR spectrometer (L-band, 
Magnettech, Germany) equipped with automatic coupling and tuning controls. Mice, under 
anesthesia (2% isofluorane), were placed in a right and left-lateral positions with their tumor 
close to the loop of the surface coil resonator. EPR spectra were acquired as single 30-sec scans. 
The instrument settings were: incident microwave power, 4 mW; modulation amplitude, 180 
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mG, modulation frequency 100 kHz; receiver time constant, 0.2 s. The peak-to-peak width of the 
EPR spectrum was used to calculate pO2 using a standard calibration curve.  
Evaluation of angiogenesis.  Texas red–conjugated dextran (mol wt 70,000; Molecular Probes, 
Eugene, OR) was prepared to 6.2 mg/mL in PBS and was injected i.v. via the tail vein at 21 μg/g 
of mouse body weight. The mice were humanely sacrificed for tissue preparation 5 minutes after 
the injection. Blood was drawn for circulating blood cell analysis by heart stick. Each tumor was 
removed and cut in half - one half was placed into a cryovial and flash frozen in liquid nitrogen 
for cytokine expression within the extracellular fluid, the other half was formalin fixed for 
immunohistochemical staining. Tumor sections were analyzed for fluorescence using confocal 
microscopy and functional blood vessels were identified and quantified using Adobe Photoshop 
CS2. 
Immunohistochemistry.  For identification of cell types within the tumors, the formalin-fixed, 
paraffin-embedded mammary tumors were stained to identify CD34+ (endothelial cells), F4/80+ 
(macrophages), and LY6G+ (neutrophils) cells, as well as hematoxylin & eosin (H&E) for tissue 
morphology. Total cell influx was analyzed by digital images captured from the entire tumors 
and quantified using Adobe Photoshop CS2 software. All immunohistochemistry was performed 
at the Histology Core at The Ohio State University. 
Evaluation of necrosis.  Upon euthanasia, the lungs from mice treated with GM-CSF or PBS 
were removed, insufflated, fixed in formalin and paraffin embedded, sectioned and stained with 
hematoxylin & eosin. Necrotic tissue within the tumors was evaluated by capturing digital 
images using a 1x objective and exposure to green fluorescent light as described (Achilles, E. G. 
et al., 2001). Necrosis was quantified using Adobe Photoshop CS2 software. 
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Tumor metastases. Upon euthanasia, the lungs from mice implanted with tumor cells and treated 
with GM-CSF or PBS were removed, insufflated, fixed in formalin, and stained with eosin. 
Tumor cell metastases were evaluated by subjecting the lungs to Bright Field light under a 
stereomicroscope. Each tumor incident was counted in a blinded manner. 
RESULTS 
Local treatment with GM-CSF slows tumor growth in a mouse model of breast cancer.  Based on 
the results of our in vitro work (Eubank, et al, 2004), we proposed that treating tumors with high 
levels of GM-CSF would alter the activity of macrophages within the tumor microenvironment, 
stimulating them to secrete  soluble VEGF receptor-1, whose endogenous role is to block 
angiogenesis.  Since tumors require the exchange of nutrients and waste to grow beyond 2mm3, 
we suspected that the overall effects of this blockade could be monitored by reduced tumor 
growth.  To test our hypothesis, we transplanted breast cancer cells into the breasts of normal 
FVB/N mice.  When tumors became palpable, we randomized the mice to treatment groups.  
Mice received intratumor injections of 0, 1, 10, 100, or 1000ng of GM-CSF three times per week 
for three weeks.  Once a week, tumor measurements were recorded.   
Mice treated with increasing doses of GM-CSF demonstrated increasingly slowed rates of tumor 
growth, up to 100ng (Figure 2A).  In these mice, there were no significant changes in body 
weight or overt clinical symptoms.  CBCs with differential analysis performed at study end 
showed no significant changes in blood compartments, even at the 100ng dose (data not shown).  
Mice treated with 1000ng showed clinical signs such as ruffled fur and lethargy with two out of 
three mice dying spontaneously before study end.  Based on these results, all subsequent studies 
used a 100ng dose. 
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To validate this method, 10 and 12 mice were treated with intratumor injections of PBS (vehicle) 
or 100ng GM-CSF three times per week.  The results of tumor growth measurements are shown 
in Figure 2B.  GM-CSF treatment significantly slowed tumor growth, demonstrating a 50% 
reduction in tumor diameter (representing a 75% reduction in tumor volume) at four weeks.  
These results were significant at a level of p < 0.001. 
GM-CSF treatment correlates with reduced lung metastasis.  Malignancy is determined by the 
ability of cancer cells to metastasize to sights such as the lung, brain, thyroid, and bone.  The 
PyMT model is an aggressive breast cancer that metastasize readily to the lung (Lin, E. Y. et al., 
2003).  Because tumor angiogenesis is an essential component of metastases and GM-CSF 
treatment induces an environment contrary to new blood vessel formation, we speculated that 
any reduction in angiogenesis would correlate with a reduction in metastases of these tumors to 
the lung.  We orthotopically injected PyMT tumor cells into a single mammary gland of normal 
FVB/N female mice.  Upon palpation, the mice were randomized into treatment groups and 
injected with PBS or 100 ng rmGM-CSF three times a week for eight weeks.  After eight weeks, 
the mice were sacrificed, the lungs insufflated, removed, fixed and stained with eosin to identify 
solid masses within the lungs (Figure 3A).  Quantification of tumor incidence indicates that 
GM-CSF treatment exudes a marked reduction in lung metastases of the mammary tumors 
compared to PBS treatment (P=0.061).  
Treatment lowers oxygen levels within the tumor proper.  Because we observe reduced tumor 
growth rates in response to GM-CSF compared to PBS, and because GM-CSF induces the 
production of a potent inhibitor to angiogenesis, sVEGFR-1, from tumor-associated 
macrophages (Eubank, et al, 2004), we hypothesized that GM-CSF treatment may reduce the 
availability of oxygen within the tumor by disrupting new blood vessel formation.  To track 
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changes in oxygen concentration in real-time within the tumors of GM-CSF-treated mice, we 
mixed lithium octa-n-butoxy 2,3-naphthalocyanine (LiNc-BuO) microcrystals with PyMT tumor 
cells and injected this mixture into the mammary fat pads of normal FVB/N female mice.  2-
dimensional electron paramagnetic resonance (EPR) analysis was performed on the day of initial 
injection and once per week, subsequently, for four weeks.  A higher resolution, 3-dimensional 
EPR reading was taken after three weeks.  Mice were sacrificed to obtain anoxic control values 
after the fourth treatment week.  Our data suggest that treatment with GM-CSF inhibits 
oxygenation of the tumor with the largest effect seen after 2 weeks of treatment (Figure 4A).  3-
D EPR imaging of PBS- and GM-CSF-treated tumors after 3 weeks illustrate a reduction in the 
concentration of oxygen throughout the GM-CSF-treated tumors, but especially near the centers 
(Figure 4B).  Distribution mapping showed the probe distribution to be uniform throughout the 
tumor, equal between groups, and limited to the tumor itself (data not shown). 
GM-CSF causes increased necrosis within the tumor and changes in necrotic patterns.  
Depriving tumors of oxygen and other nutrients should cause cell death and tissue necrosis.  
Histologic evaluation of tumor sections validated the biologic significance of lower oxygen 
levels, as tumors treated with GM-CSF had higher levels of tissue necrosis (Figure 5).  Tumor 
sections stained with H&E were viewed under a microscope using a 1X objective and laser/filter 
settings appropriate for green fluorescence.  Under such conditions, necrotic tissue within H&E 
sections will autofluoresce.  This allows for quantification of tumor necrosis as outlined in 
METHODS.  Of particular note are the patterns of necrosis observed in the two different tissues.  
Mice treated with PBS demonstrate typical focal patterns of necrosis with a single area of 
involvement near the outer surface of the tumor (Figure 5A).  In contrast, GM-CSF-treated 
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tumors reveal diffuse, multifocal patterns of necrosis, with smaller necrotic foci distributed 
throughout the tumor. 
sVEGFR expression mediates the effects of GM-CSF treatment.  We hypothesized that GM-CSF 
treatment would induce tumor-associated macrophages to express sVEGFR-1, limiting 
angiogenesis and inhibiting tumor growth.  To test this hypothesis, we orthotopically injected 
PyMT tumor cells into the mammary fat pad of normal FVB/N mice.  Upon formation of a 
palpable tumor, the mice were randomized into the following four treatment groups:  PBS, GM-
CSF, GM-CSF plus a neutralizing antibody to sVEGFR-1, or GM-CSF plus an isotype IgG 
control antibody.   
Treatment with a neutralizing antibody to sVEGFR-1 caused GM-CSF treated tumors to grow at 
rates nearly identical to vehicle-treated tumors (Figure 6, p = 0.829 vs PBS).  Growth lines for 
GM-CSF treatment alone and GM-CSF plus isotype antibody were virtually superimposable, but 
much slower than the other two groups (p = 0.025 and 0.046 vs PBS, respectively).   
DISCUSSION 
We have proposed a model whereby one might change the behavior of cells within a tumor by 
therapeutically altering the factors present in the microenvironment.  Such an approach to cancer 
therapy requires that we understand mechanisms of “tumor education” and that we identify 
factors which can stimulate cells within the tumor to adopt behaviors that will counter 
undesirable biological effects of that “education.”  This paper demonstrates our ability to do just 
that.  Here we show that we can change the activity of macrophages to affect desirable outcomes 
in a murine model of breast cancer by local administration of a factor which causes a shift 
toward a more anti-tumor phenotype.   
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These data demonstrate how GM-CSF treatment slows tumor growth and prevents lung 
metastasis in our mouse model.  In these studies we have used in vivo, intratumor oxygen 
measurement by EPR as a surrogate for angiogenic activity.  In a normal, “healthy” tumor, 
growth results in escalating oxygen demand.  This demand must be met by production of 
angiogenic factors coupled with new blood vessel growth.  EPR analysis has allowed us to track 
changes in oxygenation throughout treatment.  These studies (Figure 4) show that GM-CSF 
reduces oxygen levels within the tumors by depleting them of a major angiogenic factor, VEGF.  
Altered patterns of necrosis found in GM-CSF-treated tumors (Figure 5) illustrate the biological 
significance of the oxygen deprivation, and suggest that this blockade of angiogenic activity 
mediates the gross effects associated with intervention.  The use of a neutralizing antibody to the 
soluble receptor (Figure 6) proves that this important anti-angiogenic factor largely mediates the 
effects of GM-CSF treatment.  Since the IgG control treated group was not significantly different 
than the GM-CSF-treated group, it appears that this effect is related to the specific activity of the 
anti-sVEGFR-1 antibody and not to an antibody-mediated immune response.  Taken together, 
these data show that GM-CSF slows tumor growth by starving them of oxygen and nutrients by 
increasing levels of sVEGFR-1 within the tumor. 
We suspect that this anti-angiogenic activity can be attributed to a change in the phenotype of 
macrophages within the tumor, similar to the changes we observed in vitro, marked by the 
expression of sVEGFR-1.  Studies aimed at characterizing the gene expression patterns of tumor-
associated macrophages, neutrophils, and other cells will shed more light on the cell types that 
produce the sVEGFR-1 upon treatment with GM-CSF.   
Tumor metastasis also depends on blood vessel growth.  Not only do vessels provide a route for 
escape by hematogenous spread, but the processes required for invasion of vessels into the tumor 
 10 
can facilitate detachment of cells from the surrounding tissues and entrance into the blood stream 
(WEIDNER, N. et al., 1991).  We presume at this time that reductions in lung metastases we 
observe (Figure 3) are a direct result of impaired angiogenic activity.  However, we have also 
found significant changes in other factors within the tumor which might affect rates of tumor 
metastasis (data not shown).  Further studies will be needed to show the relative contribution of 
each to metastasis. 
We have shown that it is possible to reprogram the tumor microenvironment and change the way 
“tumor educated” cells behave in vivo using therapeutically-plausible techniques.  Such models 
provide a powerful platform for studying the involvement of macrophages and other cells in the 
processes which comprise malignant transformation.  Detailed studies of the changes invoked by 
treatment within each cell type and within the tumor organ will help us understand the role each 
cell type plays in malignant conversion and possibly identify novel therapeutic targets. 
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FIGURE LEGENDS 
Figure 1. GM-CSF alters the expression of angiogenic molecules in monocytes.   
Many breast tumors express M-CSF, which stimulates monocyte/macrophages to secrete VEGF, 
promoting a pro-angiogenic phenotype.  GM-CSF, on the other hand, makes these cells produce 
sVEGFR, which can block vascular growth.  sVEGFR will not only block the effects of VEGF 
produced by the monocytes themselves, but can bind VEGF from any source, including that 
produced by the tumor cells.  This and other effects of GM-CSF may slow tumor growth and 
hinder metastasis.  The underlying hypothesis of this paper is that local GM-CSF injection to 
create higher levels of GM-CSF within the tumor will change the phenotype of the macrophages 
within the tumor, causing them to adopt more anti-tumor, anti-angiogenic behaviors. 
Figure 2. Intratumor GM-CSF injection slows tumor growth and prolongs survival.  
(A) 8-10 week old female FVB/N mice were injected with 5 X 105 PyMT tumor cells into the #4 
mammary fat pad. Upon palpable tumor formation, mice were randomized to one of five 
treatment groups, 0, 1, 10, 100, or 1000 ng.  Mice were treated with this dose of GM-CSF by 
injection into the tumor 3X per week for three weeks.  Tumor size (tumor diameter in the 
greatest dimension) and mouse weight was measured weekly.  Mouse weight did not differ 
between groups for the duration of the study (data not shown).  Data shown represent average 
tumor size from three mice per group. 
(B) FVB/N mice were injected with PyMT tumor cells, as above.  Upon tumor formation, mice 
were randomized to treatment (100 ng GM-CSF in PBS) or vehicle (PBS alone) groups.  Mice 
were treated 3X per week until tumors reached 2 cm in their greatest diameter.  Tumor size 
(diameter in the greatest dimension) and mouse weight was measured weekly.  Mouse weight did 
not differ between groups (data not shown).  Data shown represent 10 and 12 mice for vehicle 
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and treatment groups, respectively.  Difference between groups is significant at the p < 0.001 
level when compared by ANOVA. 
Figure 3.  Local GM-CSF treatment reduces tumor metastases to lung. 
On euthanasia, lungs were removed from GM-CSF and PBS-treated mice, insufflated, fixed in 
formalin, and whole-mounted.  These lungs were then imaged on a stereo microscope and tumor 
metastases noted. 
(A)  Representative images of lungs from GM-CSF and PBS-treated mice.  Arrows show 
opacities in the lung which suggest metastatic tumor growth. 
(B)  Quantification of tumor metastases.  Data represents mean number of metastases per mouse 
±SEM over 7 mice per group. 
Figure 4. Intratumor GM-CSF treatment reduces oxygen levels within mammary tumors in vivo. 
(A) A subset of mice from studies shown in Figure 3 were given orthotopic injections of tumor 
cells containing nanoparticles of LiNC-BuO, allowing for real-time, in vivo oxygen measurement 
by electron paramagnetic resonanance imaging (EPR).  Oxygen levels in these mice were 
measured weekly by 2D EPR, and once at 3 weeks by 3D EPR.  Lines represent average oxygen 
concentration in mmHg taken from 2D EPR measurements ±SEM from 4 mice per group.  
(B) Representative samples of 3D EPR imaging (2 mice from each group) showing oxygen 
distribution throughout the tumor.   Measurements of nanoparticle density and distribution in the 
area around the tumor were made concurrently.  These measurments showed that the 
nanoparticles were limited in space to the area corresponding to the tumor proper, with uniform 
distribution of the particles throughout the tumor (data not shown).  These images were taken on 
mice treated with GM-CSF or PBS for 3 weeks. 
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Figure 5.  GM-CSF treatment may change the pattern and amount of necrosis within tumors. 
On euthanasia, tumors were removed from GM-CSF and PBS-treated mice, fixed in formalin, 
paraffin-embedded, sectioned, and stained with H&E.  Sections were then imaged using a 1X 
objective under green fluorescence conditions.  Under these conditions, necrotic tissue will 
autofluoresce, allowing for identification of necrotic and viable . 
(A)  Representative images of H&E-stained tumors under green fluorescence. 
(B)  Quantification of necrosis.  Data represents average percentage of necrotic tissue (area of 
green autofluoresence over total tumor area).  Numbers show mean ±SEM of 4 mice per group.  
Figure 6. sVEGFR neutralization restores normal tumor growth patterns.   
Normal female FVB/N mice were given orthotopic injections of 5 X 105 PyMT tumor cells as in 
Figure 3.  Upon tumor formation, mice were randomized to receive injections of PBS vehicle or 
GM-CSF (as before), or GM-CSF plus a sVEGFR blocking antibody or isotype antibody.  
Intratumor injections were given 3 times weekly for 3 weeks.  Graph shows growth of tumors as 
measured in their greatest diameter.  Circles represent mean tumor size ± SEM for each group at 
each timepoint.  Groups consisted of 4, 5, 8, and 4 mice, respectively.  p values vs PBS group: 
GM alone = 0.025, GM + aSR = 0.829, GM + Isotype = 0.046 by repeated measures ANOVA 
with Tukey post hoc testing.  
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